
Connect Biopharma Holdings Investor Relations Material
Latest events

Study Result
Connect Biopharma Holdings
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Connect Biopharma Holdings Ltd
Access all reports
Connect Biopharma Holdings Ltd is a global, clinical-stage biopharmaceutical company focused on developing innovative therapies for chronic inflammatory diseases by leveraging its expertise in T cell biology. The company is advancing a pipeline of novel small molecules and biologics, targeting various conditions such as atopic dermatitis, ulcerative colitis, and chronic pruritus. These therapies aim to address significant unmet medical needs by modulating immune system responses. Connect Biopharma's approach combines a deep understanding of T cell-driven research with proprietary Immune Modulation Technology Platform, aiming to significantly reduce the discovery time and cost for new, effective treatments. The company is headquartered in San Diego, California, and its shares are listed on the NASDAQ.
Key slides for Connect Biopharma Holdings Ltd


Corporate Presentation
Connect Biopharma Holdings Ltd


Corporate Presentation
Connect Biopharma Holdings Ltd
Latest articles
)
Upcoming IPOs to Watch in 2025
Potential IPOs in 2025 include prominent names like Shein, Databricks, Klarna, eToro, and Figma, to name a few. Let's take a closer look.
23 May 2025
)
Figma: Collaborative Design Tool Ready for IPO
Figma, the popular design platform, is preparing for a potential IPO in 2025 as it continues to reshape the future of collaborative design.
22 May 2025
)
Companies That Had Their IPO in 2024: Momentum Increasing
2024 marked a steady year for IPOs, driven by strong markets, AI momentum, and high-profile listings across industries and regions.
22 May 2025
Ticker symbol
CNTB
Country
🇺🇸 United States